Starpharma

Starpharma Partnerships

Gain a direct line to Starpharma's leadership


Be first to know our latest company updates


Watch exclusive videos accompanying major
news

Star Navigator

Partnerships

Careers

Our People & Culture

People & Culture

Corporate Governance

Shareholder Services

Stock Listing

Market Data

Annual General Meeting 2025

Annual Reports

Video Library

Investor Presentations

Updates

ASX Announcements

Why Invest

Announcements

DEP® Pipeline

DEP® Drug Delivery Platform

Dendrimer Technology

Pipeline & Products

About Starpharma

Research Publications

Our Capabilities

Our Brands

Team

Company

Home

Poppins

. Let’s explore how Starpharma can elevate your research.

Contact our Business Development team at 

 to find out more about partnering and how

our dendrimer technology can benefit your research program.

Choose the right partnership model for your research, whether it’s accessing our research-ready DEP® dendrimers compatible with a range of targeting moieties, a research collaboration, or a platform license.

Unlock new possibilities with Starpharma's cutting-edge DEP® drug delivery platform through strategic partnerships, collaborations, and licensing. Our DEP® technology, validated in clinical trials and backed by a robust intellectual property portfolio, has the potential to significantly enhance the therapeutic profile and commercial value of many drugs, including oncology chemotherapeutics, non-oncology molecules, antibody-drug conjugates (ADCs), and radiotheranostics.

Contact our business development team to explore partnership opportunities with Starpharma

Business Development
T: +61 3 8532 2700
E: 

Investigate how increased payloads, customised pharmacokinetics (PK) and biodistribution can improve efficacy and reduce toxicity in your drug delivery program.

Work alongside Starpharma’s experienced team to refine and scale your approach, ensuring seamless progression from research to GMP production.

Leverage our deep expertise to accelerate your path from concept to commercialisation while enhancing your Intellectual Property (IP) portfolio.

Companies focused on 505(b)(2) formulations

Drug delivery and target discovery companies

Developers of novel chemotherapeutic payloads

Starpharma continues to explore partnerships to expand the global presence of its commercial products, VivaGel® BV and VIRALEZE™. The company focuses on partners with strong marketing, distribution, and regulatory capabilities.

If you are interested in obtaining distribution rights for these products or would like to discuss how the DEP® platform can enhance your product or development candidate, we encourage you to contact our business development team at 

More than 350 patients have been treated with Starpharma’s DEP® drug delivery technology across multiple clinical programs.

Precise manufacturing, characterisation and scale-up: 

Allows preferential accumulation in target areas.

Flexible pharmacokinetics (PK) management:

 Customize PK and biodistribution properties of drugs to enhance and preserve efficacy while minimising toxicity.

Achieve therapeutics with high DARs in a single conjugation step not possible with established ADC approaches.

Tailor payload, linker and dendrimer size for novel therapy approaches.

 Over 20 years leading dendrimer technology, translating discovery and research into clinical and commercial products.

: Our DEP® platform employs dendrimers to improve drug performance, efficacy, and safety, enabling targeted and precisely controlled administration.

: Generate new IP and extend the patent life of drugs through our technology.

: Access our DEP® platform for performance improvement through collaborative research and licensing agreements.

: We have established successful partnerships with leading pharmaceutical companies and research institutes.

Our Partnership Models

Strategic Alliance

Acceleration

DEP® Platform Access

R&D Partnership

Star Navigator